Decibel Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Update
10 août 2022 16h30 HE
|
Decibel Therapeutics, Inc.
- Announced positive data from interim analysis of Phase 1b clinical trial of DB-020 in patients receiving cisplatin chemotherapy; data support continued development of DB-020 as a potential therapy...
Decibel Therapeutics Reports Positive Data from Interim Analysis of Ongoing Phase 1b Clinical Trial of DB-020 in Patients Receiving Cisplatin Chemotherapy
28 juin 2022 07h00 HE
|
Decibel Therapeutics, Inc.
- 87% of patients who experienced ototoxicity in their placebo-treated ear were protected from ototoxicity in their DB-020-treated ear – - Data support continued development of DB-020 as a potential...
Decibel Therapeutics to Present at the Jefferies Global Healthcare Conference
03 juin 2022 07h30 HE
|
Decibel Therapeutics, Inc.
BOSTON, June 03, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics to Present at the H.C. Wainwright Global Investment Conference
17 mai 2022 07h30 HE
|
Decibel Therapeutics, Inc.
BOSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting
02 mai 2022 07h30 HE
|
Decibel Therapeutics, Inc.
BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
18 mars 2022 07h00 HE
|
Decibel Therapeutics, Inc.
- Key anticipated catalysts in 2022 include submission of IND and/or CTA for DB-OTO and results from interim analysis from Phase 1b trial of DB-020 for cisplatin-induced hearing loss - - Research...
Decibel Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
10 févr. 2022 16h30 HE
|
Decibel Therapeutics, Inc.
BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics Reports on Continued Progress of Lead Gene Therapy Product Candidate DB-OTO and Presents Promising Preclinical Data Supporting Importance of Cell-Selective Transgene Expression Across Gene Therapy Pipeline
09 févr. 2022 18h00 HE
|
Decibel Therapeutics, Inc.
- Podium presentation at Association for Research in Otolaryngology Annual MidWinter Meeting highlighting DB-OTO dose-ranging studies with expression analysis, functional recovery and tolerability...
Decibel Therapeutics to Present at the 45th Annual Association for Research in Otolaryngology (ARO) Meeting
31 janv. 2022 07h00 HE
|
Decibel Therapeutics, Inc.
BOSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics to Present at the H.C. Wainwright BioConnect Conference
04 janv. 2022 07h00 HE
|
Decibel Therapeutics, Inc.
BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...